AbbVie Reports Results of Rinvoq (upadacitinib) in P-II/III SELECT-AXIS 1 Study for Patients with Ankylosing Spondylitis

 AbbVie Reports Results of Rinvoq (upadacitinib) in P-II/III SELECT-AXIS 1 Study for Patients with Ankylosing Spondylitis

AbbVie Reports Results of Rinvoq (upadacitinib) in P-II/III SELECT-AXIS 1 Study for Patients with Ankylosing Spondylitis

Shots:

  • The P-II/III SELECT-AXIS 1 Trial involves assessing of Rinvoq (15mg, qd) vs PBO in patients with active AS who are bDMARD-naïve and had an inadequate response to at least two NSAIDs or intolerance to/contraindication for NSAIDs, evaluating its safety and efficacy
  • The study resulted in achieving 1EP as ASAS 40 @14 wks. (52% vs 26%), no new safety risks detected, Presented at ACR/ARP Annual Meeting 2019
  • Rinvoq is a JAK inhibitor, currently being evaluated in P-III studies for psoriatic arthritis, Crohn’s disease, atopic dermatitis, UC and giant cell arteritis and is an approved therapy for adult patients with moderately to severely active RA. Rinvoq has also received CHMP’s positive opinion and is currently awaiting for EC’s approval

Click here to­ read full press release/ article | Ref: AbbVie  | Image: Daily Herald

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post